Innoviva, Inc. (NASDAQ:INVA) Shares Acquired by Caxton Associates LP

Caxton Associates LP grew its stake in Innoviva, Inc. (NASDAQ:INVA) by 115.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,561 shares of the biotechnology company’s stock after acquiring an additional 19,076 shares during the quarter. Caxton Associates LP’s holdings in Innoviva were worth $542,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of INVA. Bessemer Group Inc. increased its stake in shares of Innoviva by 333.5% in the 1st quarter. Bessemer Group Inc. now owns 2,211 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 1,701 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Innoviva by 124.0% during the 1st quarter. GAMMA Investing LLC now owns 2,262 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 1,252 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Innoviva by 342.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,410 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 5,736 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Innoviva during the 1st quarter worth about $138,000. Finally, Quadrant Capital Group LLC increased its position in shares of Innoviva by 13.2% during the 4th quarter. Quadrant Capital Group LLC now owns 9,042 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 1,056 shares during the last quarter. 99.12% of the stock is owned by institutional investors and hedge funds.

Innoviva Stock Performance

Shares of INVA opened at $18.99 on Wednesday. The stock has a 50-day simple moving average of $16.52 and a 200-day simple moving average of $15.81. The company has a debt-to-equity ratio of 0.63, a quick ratio of 9.17 and a current ratio of 10.42. The stock has a market capitalization of $1.19 billion, a PE ratio of 8.55 and a beta of 0.57. Innoviva, Inc. has a 1 year low of $12.22 and a 1 year high of $19.08.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter. The business had revenue of $77.50 million during the quarter. Innoviva had a return on equity of 28.94% and a net margin of 58.21%. On average, analysts predict that Innoviva, Inc. will post 1.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

INVA has been the subject of a number of recent analyst reports. StockNews.com downgraded Innoviva from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Innoviva in a report on Tuesday.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.